Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen

We have compared the ability of several nanosized bioceramic particles including negatively charged silica (SiO2), neutrally charged hydroxyapatite (HA) and positively charged zirconia (ZrO2) nanoparticles as non-viral vectors for efficient in vivo gene delivery. A mixture of highly monodispersed aqueous suspension of HA or SiO2 nanoparticles, coated with protamine sulfate (PS), complexed efficiently with plasmid DNA and significantly enhanced transgene expression in vitro. In comparison, ZrO2 nanoparticles gave poor transfection efficiency under similar conditions tested. It was also determined that, under the same conditions, PS-SiO2-DNA, but not PS-HA-DNA-nanoplexes, were able to mediate efficient transgene expression in vitro in the presence of 50% serum. Intraperitoneal injections of PS-SiO2-luciferase DNA nanoplexes targeted the highest level of transgene expression in the spleen of recipient mice that lasted for more than 48 h. Injection of PS-SiO2-pNGVL-hFLex-MUC-1 nanoplexes was able to mediate the production of Flt-3L in the sera of recipient mice. Simultaneously, the production of Flt-3L was accompanied by the stimulation of IL-2 and interferon-γ (IFN-γ). Most importantly, the injection of PS-SiO2-pNGVL-hFLex-MUC-1 nanoplexes could mount potent anti-tumour specific immune responses that led to the subsequent regression of parental tumor cells containing the muc-1 determinant.

[1]  R. Mebius,et al.  Structure and function of the spleen , 2005, Nature Reviews Immunology.

[2]  Leaf Huang,et al.  LPD nanoparticles--novel nonviral vector for efficient gene delivery. , 2002, Methods in molecular medicine.

[3]  M. Hashida,et al.  Pharmacokinetics of Plasmid DNA-Based Non-viral Gene Medicine. , 2005, Advances in genetics.

[4]  H. Lipps,et al.  Designing nonviral vectors for efficient gene transfer and long-term gene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  J. Behr,et al.  Development of plasmid and oligonucleotide nanometric particles , 2002, Gene Therapy.

[6]  R. DeMatteo,et al.  In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  I. Khalil,et al.  Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery , 2006, Pharmacological Reviews.

[8]  M. Bureau,et al.  Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation , 2003, Gene Therapy.

[9]  Kinam Park,et al.  Polycation gene delivery systems: escape from endosomes to cytosol , 2003, The Journal of pharmacy and pharmacology.

[10]  Ronald G. Crystal,et al.  Genetic medicines: treatment strategies for hereditary disorders , 2006, Nature Reviews Genetics.

[11]  T C Yih,et al.  Engineered nanoparticles as precise drug delivery systems , 2006, Journal of cellular biochemistry.

[12]  G. Georgiev,et al.  Gene transfer approaches in cancer immunotherapy , 2004, Gene therapy.

[13]  A. Kondo,et al.  Nanoparticles for the delivery of genes and drugs to human hepatocytes , 2003, Nature Biotechnology.

[14]  R. DeMatteo,et al.  Natural Killer Dendritic Cells Have Both Antigen Presenting and Lytic Function and in Response to CpG Produce IFN-γ via Autocrine IL-121 , 2005, The Journal of Immunology.

[15]  A. Logan,et al.  Barriers to gene delivery using synthetic vectors. , 2005, Advances in genetics.

[16]  K. Niihara,et al.  Wear properties of alumina/zirconia composite ceramics for joint prostheses measured with an end-face apparatus. , 2004, Bio-medical materials and engineering.

[17]  K. Hui,et al.  Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides , 2002, Gene Therapy.

[18]  E. Wagner,et al.  Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  D. Luo,et al.  A self-assembled, modular DNA delivery system mediated by silica nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Y. Byun,et al.  Low molecular weight protamine: a potential nontoxic heparin antagonist. , 1999, Thrombosis research.

[21]  Dan Luo,et al.  Cellular Fate of a Modular DNA Delivery System Mediated by Silica Nanoparticles , 2008, Biotechnology progress.

[22]  H. Lipps,et al.  Towards safe, non-viral therapeutic gene expression in humans , 2005, Nature Reviews Genetics.

[23]  M. Davis,et al.  Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. , 2001, Current opinion in molecular therapeutics.

[24]  K. Khor,et al.  Temperature driven morphological changes of chemically precipitated hydroxyapatite nanoparticles. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[25]  K. Hui,et al.  Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression , 2006, Gene Therapy.

[26]  Wim E. Hennink,et al.  Artificial viruses: a nanotechnological approach to gene delivery , 2006, Nature Reviews Drug Discovery.

[27]  K. Khor,et al.  Radio frequency (RF) suspension plasma sprayed ultra-fine hydroxyapatite (HA)/zirconia composite powders. , 2003, Biomaterials.

[28]  C. Lawson Strategies for Gene Transfer to Solid Organs , 2006 .

[29]  T. Niidome,et al.  Gene Therapy Progress and Prospects: Nonviral vectors , 2002, Gene Therapy.

[30]  Yong Wang,et al.  Delivery of Viral Vectors to Tumor Cells: Extracellular Transport, Systemic Distribution, and Strategies for Improvement , 2006, Annals of Biomedical Engineering.